Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural Sedation

• Published in: Journal of clinical pharmacology Vol. 65; no. 5; p. 637
• Main Authors: Arsanious, Jason, Rowland, Angela, Sorich, Michael J, Hopkins, Ashley M, Alfred, Sam, Rowland, Andrew
• Format: Journal Article
• Language: English
• Published: England 01.05.2025
• Subjects: Adult; Area Under Curve; Drug Interactions; Female; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - adverse effects; Hypnotics and Sedatives - pharmacokinetics; Male; Midazolam - administration & dosage; Midazolam - adverse effects; Midazolam - pharmacokinetics; Middle Aged; Models, Biological; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - pharmacokinetics; Ritonavir - pharmacology; Young Adult; toxicity; procedural sedation; midazolam; drug interaction; ritonavir

Intravenous midazolam is frequently used for procedural sedation. Use of ritonavir containing antivirals in patients requiring procedural sedation with intravenous midazolam is postulated to increase the risk or prolong the consequences of exposure related adverse events. The primary objective of th...